ABBOTINDIA.NSE · Abbott India Limited

-

Please sign in to comment on ABBOTINDIA.NSE

1 Comment

Admin

4 years, 1 month ago

Abbott India Limited is currently in a long term uptrend where the price is trading 11.8% above its 200 day moving average.

From a valuation standpoint, the stock is 60.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 7.7.

Abbott India Limited's total revenue rose by 1.6% to $11B since the same quarter in the previous year.

Its net income has dropped by 5.1% to $2B since the same quarter in the previous year.

Finally, its free cash flow fell by 6.0% to $3B since the same quarter in the previous year.

Based on the above factors, Abbott India Limited gets an overall score of 2/5.

ISIN	INE358A01014
Exchange	NSE
CurrencyCode	INR
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

Dividend Yield	1.3%
Target Price	32786.25
Market Cap	645B
Beta	-0.03
PE Ratio	48.31

ABOUT

Abbott India Limited

Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It provides anti-infective, cardio-diabeto, hepatology, hormones, neuro-psychiat, hepatic, gennext, and consumer care products. The company was founded in 1910 and is headquartered in Mumbai, India. Abbott India Limited is a subsidiary of Abbott Capital India Limited.

ABBOTINDIA.NSE · Abbott India Limited

-

Abbott India Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Abbott India Limited using a moving average strategy